EXL delivered a robust Q4 2025 with revenue growing 12.7% year-over-year to $542.6 million. The company saw significant growth in its Healthcare and Life Sciences segment and authorized a new $500 million stock repurchase program. Profitability improved with Adjusted Diluted EPS rising 15% to $0.50.
Revenue increased 12.7% year-over-year to $542.6 million, driven by strong demand for AI-native solutions.
The Board authorized a new $500 million common stock repurchase program effective February 28, 2026.
Healthcare and Life Sciences was the fastest-growing segment in Q4, with revenue up 26.2% year-over-year.
Full-year 2026 guidance suggests continued momentum with expected revenue growth of 9% to 11%.
For the full year 2026, EXL expects revenue between $2.275 billion and $2.315 billion and adjusted diluted EPS between $2.14 and $2.19.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance